What can be done about fatty livers caused by obesity?

06.2026
Author Dr. Martin Claßen, Bremen

With the growing numbers of overweight and obese children, we are seeing more and more young people with higher liver function test results caused by fatty liver hepatitis. Sonography shows that the liver parenchyma has a higher echogenicity and increased intrahepatic sound weakening. Recently, the term “Metabolic dysfunction-associated steatotic liver disease or steatohepatitis (MASLD/MASH)” has become established for these symptoms. As a result of the risk of liver fibrosis or even liver cirrhosis, MASH is considered a serious complication of being overweight and must therefore be taken seriously.

Changes to lifestyle are frequently ineffective, which means that surgical procedures to reduce calorie intake or absorption (bariatric surgery) are among the treatment options, including for young people. In the USA, 101 adolescents (average age 17.5 ± 2.1 years, 68% female, with a BMI of 47.1 ± 8.4 kg/m2) underwent bariatric surgery. At the time the surgery was performed, 76% had higher levels of transaminases, 61% were histologically proven to have MASLD, and 45% had liver fibrosis. After a year, the average BMI fell by 12.9 ± 7.9 kg/m2. The alanine aminotransferase (ALT) values were reduced from 41 ± 38 to 27 ± 33 IU/L. After a year, 35% of the adolescents still had high ALT values. A control biopsy of the liver was carried out on 23 patients: the MASH had disappeared in 50% of them, and the fibrosis also disappeared in half of this group (p < 0.001).

Comment: We should note first of all that MASH can occur even in people with a normal weight, and that if there is evidence of steatosis, other chronic liver diseases such as Wilson's disease must be ruled out. If this has happened and the patient is overweight/obese, clearly the first step is to try to change their diet (reducing overall energy intake, in particular of easily absorbable carbohydrates such as sucrose and fructose).

No medication has yet been approved for children/young people with MASH – though resmetirom, a partial agonist of the thyroid hormone receptor β (THR-β), was introduced for adults with MASH and liver fibrosis in 2025. Semaglutide is also effective against MASH.

For children and young people with MASH, treatment of obesity is paramount. This is a lengthy and often frustrating process, both for the patients themselves and for the people providing treatment. The data from this study are another indication that bariatric surgery produces better results for overweight/obese children than changes to diet and playing sports. It is very heartening to see from the results that not only does their weight/BMI go down, but inflammation in the liver is also reduced (lower ALT) and the risk of fibrosis is lower – further justification for choosing surgery.

As obesity poses multiple health risks (with MASH being a particularly serious example) and reduces both life expectancy and quality of life, it must be taken very seriously at a much earlier stage, and countermeasures must be introduced when children are toddlers or in the early years of school. If the problem has got out of control by adolescence, bariatric surgery is clearly an effective option, especially if there is already evidence of fibrosis in a young person with MASH/MASLD. A comparison with the GLP-1 receptor agonists, which have not yet been approved for the indication of weight reduction in this age group, would also be scientifically significant.
 

Reference:
Sundaram, S. S., Kelsey, M., Nadeau K. J. et al. (2026) Resolution of Biochemical and Histologic Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adolescents with Severe Obesity after Metabolic Bariatric Surgery. The Journal of Pediatrics, 2026, 291. DOI: 10.1016/j.jpeds.2025.114944